leadf
logo-loader
viewMGC Pharmaceuticals Ltd

MGC Pharmaceuticals sets sights on being one of first cannabis-related companies listed on London Stock Exchange

The company has welcomed a new guidance note from the FCA and is confident it meets the requirements for LSE listing.

MGC Pharmaceuticals Ltd - MGC Pharmaceuticals plans to be one of the first cannabis-related companies listed on the London Stock Exchange
MGC Pharma will now fast-track the finalisation of its listing submission

MGC Pharmaceuticals Ltd (ASX:MXC) (OTCMKTS:MGCLF) (FRA:H5O) welcomes new guidance from the Financial Conduct Authority (FCA) on its approach to assessing applications from cannabis-related companies for listing on the London Stock Exchange (LSE).

The new guidance advises that overseas companies may be admitted to the Official List, provided they are satisfied the Proceeds of Crime Act 2002 (PoCA) does not apply and companies otherwise satisfy the criteria for listing.

MGC and its UK advisors are confident that the MGC Pharma business and operations fully comply with the new FCA listing approval requirements.

“Well-placed to push ahead”

MGC Pharma is now accelerating its plans to be one of the first cannabis-related companies listed on the LSE.

Co-founder and managing director Roby Zomer said: “We started the process of seeking a listing in the UK over a year ago and are very pleased to see the FCA’s guidance note as we believe we are now well-placed to push ahead and be one of the first cannabis-related companies to list in the UK.

“MGC Pharma has established a global operation and we believe a UK listing will provide a unique opportunity not only for the company in terms of broadening access to capital markets but also for the large and sophisticated UK investment community seeking exposure to the fast-growing global medicinal cannabis market.”

Updating documentation

MGC Pharma’s LSE listing status has been pending approval following lodgement of the company’s prospectus, legal opinions and listing documents in December 2019.

This new guidance has now paved the way for the company’s LSE listing application to proceed and the company has now commenced updating the documentation for submission under these new LSE listing rules.

Quick facts: MGC Pharmaceuticals Ltd

Price: 0.024 AUD

ASX:MXC
Market: ASX
Market Cap: $39.38 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MGC Pharmaceuticals Ltd named herein, including the promotion by the Company of MGC Pharmaceuticals Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Synairgen plans after £80m share sale to fund crucial trial of breakthrough...

Synairgen PLC's Richard Marsden (LON:SNG) talks to Proactive London's Katie Pilbeam about the £80m share placing to finance its lead drug through final-stage clinical trials in patients with severe coronavirus (COVID-19). Marsden explains the reason behind involving 900 patients in 20...

6 hours, 33 minutes ago

2 min read